Literature DB >> 17458806

[Surgical treatment of diplopia in Graves' orbitopathy].

E M Pitchon1, G Klainguti.   

Abstract

BACKGROUND: The correction of oculomotor disorder in Grave's disease is applied on pathological extraocular muscles. Based on the global muscular restriction (bilateral forced duction test) and angular measurements, we have used a non-adjustable technique. PATIENTS AND METHODS: We performed a retrospective analysis of 21 patients (23 operations) with thyroid-associated orbitopathy operated for persisting diplopia. The angles of deviation in the 9 diagnostic directions of gaze and the field of binocular vision were measured with the Harm's tangent scale before and after surgery. Sixteen patients were operated only on vertical muscles. The mean follow-up was 45 months.
RESULTS: 76 % of the patients (95 % confidence interval [CI], 58-94 %) obtained a large and centred field of binocular vision without prisms. 14 % (95 % CI, 0-29 %) had binocular vision with the use of prisms. Diplopia persisted in one patient despite 3 operations. Taking into consideration the interventions done before the patient was referred to us, the reintervention rate was 13 % (95 % CI, 0-28 %).
CONCLUSIONS: A binocular field of vision can be successfully restored in the majority of patients with Graves' orbitopathy, using a non-adjustable surgical technique.

Entities:  

Mesh:

Year:  2007        PMID: 17458806     DOI: 10.1055/s-2007-962903

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  2 in total

1.  Factors Predicting the Success of Combined Orbital Decompression and Strabismus Surgery in Thyroid-Associated Orbitopathy.

Authors:  Meng-Wei Hsieh; Chih-Kang Hsu; Pao-Cheng Kuo; Hsu-Chieh Chang; Yi-Hao Chen; Ke-Hung Chien
Journal:  J Pers Med       Date:  2022-01-31

2.  Intraoperative relaxed muscle positioning technique results in a tertiary Center for Thyroid Orbitopathy Related Strabismus.

Authors:  Ahmet Murat Sarici; Burak Mergen; Velittin Oguz; Cezmi Dogan
Journal:  BMC Ophthalmol       Date:  2018-11-23       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.